| Summary: | Background: Acute watery diarrhea is common cause of morbidity and mortality in
children. Vomit also complicates the rehydration management, although antiemetics are
not recommended within standard medical protocol. Domperidone is common prescribed
antiemetics for diarrhea and no adverse effects reported in such cases. However, adequate
evidence to supports that domperidone benefits in reducing vomiting secondary to acute
watery diarrhea in children.
Objective: This study aimed to measure the benefits of domperidone compared with
placebo in reducing vomit secondary to acute watery diarrhea in children.
Methods: We conducted a randomized double-blind controlled trial in Emergency Room
and Pediatric Clinic at Dr Sardjito Hospital, Wates Distric Hospital, and Soeradji
Tirtonegoro Hospital between August to September 2007. We recruited infants and
children aged 2 mo to 6 years with vomit secondary to acute watery diarrhea. Subjects
were randomized to receive either domperidon or placebo. The outcomes of the study
were occurrence of vomiting, vomit frequency, diarrhea frequency during rehydration,
and diarrhea duration.
Result: Domperidone decreased overall vomit proportion (overall relative risk reduction
0.89, 95% CI 0.7 to 0.95, NNT 1) and decreased overall vomit frequency during
rehydration (overall episode reduction -3.26 , 95% CI -3.65 to -2.86). There was no
significant difference in diarrhea duration and frequency between groups and no side
effects were reported.
Conclusion: Domperidone significantly decreases proportion and frequency of vomit
during rehydration without increasing the frequency and duriation of diarrhea.
Domperidone is also safe for 2 months to 6 year old children.
|
|---|